Search research articles
Contact Us
Filters
Showing results (201-210 of 274) with videos related to
Page
of 28
Sort By:
Cancer Medicine
|
August 16, 2014
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
Taofeek K Owonikoko, Guojing Zhang, Xingming Deng, et al.
The Lancet. Global Health
|
June 14, 2024
Global health for rare diseases through primary care
Gareth Baynam, Adam L Hartman, Mary Catherine V Letinturier, et al.
Cancer Chemotherapy and Pharmacology
|
August 4, 2017
Phase I study of veliparib in combination with gemcitabine
Ronald Stoller, John C Schmitz, Fei Ding, et al.
Gynecologic Oncology
|
January 23, 2017
A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers
Kim A Reiss, Joseph M Herman, Deborah Armstrong, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Biomarkers
Christopher A Brown, Sandhitsu R Das, Katheryn A Q Cousins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2011
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study
John F de Groot, Kathleen R Lamborn, Susan M Chang, et al.
Cancer Research
|
July 29, 2011
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas
Shivaani Kummar, Alice Chen, Jiuping Ji, et al.
Journal of Neuro-Oncology
|
January 25, 2017
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas
Lakshmi Nayak, John de Groot, Jeffrey S Wefel, et al.
Gynecologic Oncology
|
February 21, 2021
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study
Jessica Gillen, Austin Miller, Katherine M Bell-McGuinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2009
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies
Shivaani Kummar, Robert Kinders, Martin E Gutierrez, et al.
Page
of 28
Search research articles
Search
Showing results (201-210 of 274) with videos related to
Sort By:
Page
of 28
Cancer Medicine
|
August 16, 2014
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
Taofeek K Owonikoko, Guojing Zhang, Xingming Deng, et al.
The Lancet. Global Health
|
June 14, 2024
Global health for rare diseases through primary care
Gareth Baynam, Adam L Hartman, Mary Catherine V Letinturier, et al.
Cancer Chemotherapy and Pharmacology
|
August 4, 2017
Phase I study of veliparib in combination with gemcitabine
Ronald Stoller, John C Schmitz, Fei Ding, et al.
Gynecologic Oncology
|
January 23, 2017
A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers
Kim A Reiss, Joseph M Herman, Deborah Armstrong, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Biomarkers
Christopher A Brown, Sandhitsu R Das, Katheryn A Q Cousins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2011
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study
John F de Groot, Kathleen R Lamborn, Susan M Chang, et al.
Cancer Research
|
July 29, 2011
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas
Shivaani Kummar, Alice Chen, Jiuping Ji, et al.
Journal of Neuro-Oncology
|
January 25, 2017
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas
Lakshmi Nayak, John de Groot, Jeffrey S Wefel, et al.
Gynecologic Oncology
|
February 21, 2021
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study
Jessica Gillen, Austin Miller, Katherine M Bell-McGuinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 15, 2009
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies
Shivaani Kummar, Robert Kinders, Martin E Gutierrez, et al.
Page
of 28